|
[Print version, pdf]
Select Disease Site
Department
of Clinical Trials Contact Information
Brain
Breast
Colorectal
Genitourinary
Gynecologic
Head and Neck
Hematologic
Melanoma
and Sarcoma
Thoracic
UGI
Department of Clinical Trials Contact Information
Name / Email |
Title |
Phone |
Pager |
| Patricia Sharpe |
Director,
Clinical Research |
350-7887 |
|
| Joni Shortt |
Supervisor Oncology Research,
Gyn Research Nurse |
350-8913 |
235-9983 |
| Lisa Morgan |
Screening & Prevention Nurse, Genitourinary,
Thoracic, and Brain Research Nurse |
350-7878 |
239-2465 |
| Theo Beiter |
Clinical Research Coordinator, UGI, Melanoma, and
Colorectal Coordinator |
350-3093 |
122-8970 |
| Karen Sather |
Clinical Research Coordinator, Breast, Head and Neck,
and Lymphoma Coordinator |
350-5664 |
122-2289 |
| Chableau Scott |
Oncology Document Specialist |
350-3639 |
|
| |
|
350-8707 |
|
Table of
Contents
Glioblastoma
RTOG
0825 Phase III Double Blind Placebo Controlled
Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolamide Plus
Bevacizumab VS. Conventional Concurrent Chemoradiation and Adjuvant
Temozolamide in Patients with Newly Diagnosed Glioblastoma
Meningioma
RTOG
0539: Phase II Trial
of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate and
High-Risk Meningiomas
Glioma
RTOG
0834 Avastin and Temozolomide Following Radiation and
Chemotherapy for Newly Diagnosed Glioblastoma
Multiforme: A Phase II Study
Other
CCCWFU
91105: Phase III Double Blind, Placebo Controlled Study of
Donepezil in Irradiated Brain Tumor Patients
Table of
Contents
Neoadjuvant
ACOSOG
Z1031: A Randomized Phase III Trial Comparing 16 to 18 Weeks of
Neoadjuvant Exemestane (25 mg daily),
Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with clinical Stage II and III Estrogen
Receptor Positive Breast Cancer
CALGB
40603: Randomized
Phase II 2x2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant
Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/Her2-Negative Resectable Breast Cancer.
NSABP
B-41:A Randomized
Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing
the Combination of Trastuzumab Plus
Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic
Complete Response
NSABP
FB-6/VEG 110264: A Phase II Clinical Trial of Four Cycles of
Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given
Concurrently with Pazopanib as Neoadjuvant Therapy Followed by Postoperative
Pazopanib for Women with Locally Advanced Breast Cancer.
ACOSOG
Z1071: A Phase II Study
Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node
Dissection Following Preoperative Chemotherapy in Women With Node Positive
Breast Cancer (T1-T4, N1-N2, M0) at Initial Diagnosis.
Adjuvant
NSABP
B-43: A
Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with
Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ
Resected by Lumpectomy
ECOG
E5103:A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel
with Bevacizumab or Placebo in
Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (HER2-Negative)
B-46-I/USOR
07132: A Phase III Clinical Trial Comparing the
Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with
Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
CTSU/ECOG
PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized
Options for Treatment TAILORx Trial (HER2-Negative )
Adjuvant /
Metastatic
CALGB
40502: A Randomized Phase
III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast
Cancer.
CTSU / NCCTG N0733: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane.
Cancer Control / Prevention
SenoRX (S07-002): A Mulit-Site Prospective, Non Randomized Study Utilizing the Contura Multi-Lumen Balloon (MLB) Breast Brachytherapy applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use.
URCC
1105: Prevention of Delayed
Nausea: A Phase III, Double Blind,
Placebo Controlled Trial
SWOG
S0702: A Prospective
Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis
of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting on Zoledronic Acid Treatment.
SWOG
S0715: A Randomized Phase
III Placebo-Controlled Trial of Acetyl-Lcarnitine (ALC) for the
Prevention of Taxane Induced Neuropathy
Table of
Contents
Colon
CTSU
E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin, and
Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab, in Patients
with Stage II Colon Cancer at High Risk for Recurrence to Determine
Prospectively the Prognostic Value of Molecular Markers
CALGB 80702: A Phase III trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
Rectum
No Clinical Trials Available
Metastatic /
Advanced
CALGB
80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or
Oxaliplatin/5-FU/Leucovorin With Bevacizumab, or Cetuximab (C225), or With the
Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic
Adenocarcinoma of the Colon
Table of
Contents
Prostate
CTSU
MDA-3410: A Prospective Randomized Phase III Trial Comparing
Consolidation Therapy with or without Strontium-89 following Induction
Chemotherapy in Androgen-independent Prostate Cancer.
Bladder
No Clinical Trials Available
Renal
CTSU E2805: A Randomized,
Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus
Placebo in Patients with Resected Renal Cell Carcinoma.
Cancer
Control / Prevention
2006.02.04: A Longitudinal
Study of Quality of Life for Prostate Cancer Patients
CALGB
70604: A
Randomized Phase III Study of Standard Dosing using Longer Dosing Interval of
Zoledronic Acid in Metastatic Cancer
Table of
Contents
Cervix
GOG
0219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB AND IVA Cervical Carcinoma Limited to the Pelvis. (Temporarily Closed to Accrual)
GOG
0240: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab vs. the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Endometrial
GOG
0086P: A Three Arm Randomized Phase II Study of
Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus and
Ixabepione, Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III
or IVA, Stage IVB, or Recurrent Endometrial Cancer.
GOG
0249: A Phase III Trial of Pelvic Radiation
Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin
Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
GOG
0248: A
Randomized Phase II Trial of Temsirolimus or the Combination of Hormonal
Therapy Plus Temsirolimus in Women with Advanced or Recurrent Endometrial
Carcinoma – Temporarily Closed to accrual
GOG
0238: A
Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly
Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine
Corpus
Ovarian, Primary Peritoneal, Fallopian Tube
GOG
0252: Phase III Clinical Trial of Bevacizumab
with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary
Peritoneal Carcinoma
GOG
0212: A Randomized Phase III Trial of Maintenance Chemotherapy
Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103_(IND#70177), Versus No
Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary
Peritoneal Cancer Who Achieve A Complete Clinical Response to Primary
Platinum/Taxane Chemotherapy.
BI
1199.15: Multicenter, randomized, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with Carboplatin and Paclitaxel compared to placebo plus Carbopatin and Paclitaxel in patients with advanced ovarian cancer
GOG
0213: A Phase
III Randomized Controlled Clinical Trial of Carboplatin and Paciltaxel Alone or
in Combination with Bevacizumab Followed by Bevacizumab and Secondary
Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary
Peritoneal and Fallopian Tube NCI-SUPPLIED AGENTS: BEVACIZUMAB
Millennium
C14006: A phase
2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of
Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian,
Fallopian Tube, or Primary Peritoneal Carcinoma
GOG
0187: Phase II
Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy
MORAB-003-004: A Randomized, Double-Blind, Placebo-Controlled, Phase
III Study to Assess the efficacy and Safety of Weekly Farletuzumab (MORAB-003)
in Combination with Carbloplatin and Taxane in Subjects with Platinum-Sensitive
Ovarian Cancer in First Relapse
Uterine Sarcoma
GOG
0250: A
Radnomized Phase III Evaluation of Docetaxeland Gemcitabine plus G-CSF With Bevacizumab, versus Docetaxel and Gemcitabine plus G-CSF with placebo in the treatment of recurrent or advanced
Leiomyosarcome of the uterus. NCI supplied agent: Bevacizumab
Vulva
No Clinical Trials Available
Gestational
Trophoblastic Neoplasiaa
No Clinical Trials Available
Tissue Collection
GOG
0136: Acquisition
of Human Gynecologic Specimens and Serum to be Used in Studying the Causes,
Diagnosis, Prevention, and Treatment of Cancer
Miscellaneous
ChemoFX: An Observational, Longitudinal, Multi-Center Study Examing Outcomes Associated
with the Use of the ChemoFx Assay in Solid Tumor Malignancies
Table of
Contents
Squamous
Cell
RTOG
0920: A Phase III Study of Postoperative Radiation
Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.
Nasopharyngeal
No Clinical Trials Available
Metastatic
ECOG
E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.
Table of Contents
Leukemia
No Clinical Trials Available
Lymphoma
Hodgkin’s Disease
No
Clinical Trials Available
Non-Hodgkin’s
No
Clinical Trials Available
Multiple
Myeloma
CALGB
70604: A
Randomized Phase III Study of Standard Dosing using Longer Dosing Interval of
Zoledronic Acid in Metastatic Cancer
Table of
Contents
Skin
No Clinical Trials Available
Sarcoma
No Clinical Trials Available
Table of
Contents
Non-Small Cell
Adjuvant
ECOG
1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with
or without Bevacizumab for Patients with Completely Resected Stage IB – IIIA
NSCLC
RTOG
0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located NSCLC in Medically Inoperable Patients.
RTOG
0618: Phase II
Trial of Stereotactic Body Radiation (SBRT) in the Treatment of Patients with
Operable Stage I/II NSCLC
Stage III
PROCLAIM:
Phase III Study of Pemetrexed, Cisplatin & Radiotherapy Followed by Consolidation Pemetrexed VS Etoposide, Cisplatin & Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced Stage III NSCLC Other than Predominantly Squamous Histology
Advanced /
Metastatic(stage III/IV)
CALGB
30607:
Randomized, Phase II, Double-Blinded Placebo-Controlled Trial of Sunitinib as
Maintenance Therapy in Non-Progressing Patients Following an Initial Four
Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV
Non-Small Cell Lung Cancer
Epidemiology
SWOG
S0424: Molecular Epidemiology Case- Series Study of Non-Small Cell
Lung Cancer in Smoking and Non-Smoking Women and Men (closed to smokers)
Small Cell
Limited
CALGB
30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.
Extensive
CALGB
30504:
Combination Cisplatin, Etoposide, and Sunitinib Maleate for Untreated Extensive Stage Small Cell Lung Cancer.
Mesothelioma
No Protocols available for this site
Table of
Contents
Pancreas
ACOSOG
Z5041: A Phase II Study of
Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative
Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma
RTOG
0848: A Phase III Trial Evaluating Both Erlotinib and
Chemoradiation as Adjuvant Treatment for Patients with Resected Head of
Pancreas Adenocarcinoma
Stomach
No Clinical Trials Available
Esophagus
ACOSOG
Z4051: A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab plus Radiation Therapy followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus.
Gallbladder
SWOG S0941: Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma.
Gist
No Clinical Trials Available
Liver
CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
Table of
Contents
|